Tampa, Florida, United States – TheNewswire – November 20, 2025 - CTT Pharmaceutical Holdings, Inc.(OTCQB:CTTH) is pleased to announce that the CEO of CTT Pharma will issue a letter to shareholders on December 2, 2025. The letter will outline several initiatives underway that will advance CTT’s strategic direction, including updates on our S-1 filing, which will allow CTT to become a full SEC reporting company.  Thus allowing CTT access to funding from our equity line of credit, and help accelerate growth by monetizing the company’s patents.  The letter will also include information about ongoing operational initiatives including steps toward preparing for manufacturing capabilities, as well as updates on strategic partners who are aligned with CTT’s commercialization strategy.

Finally, shareholders will receive an update on the recent submission of our peer-reviewed scientific manuscript which brings to light the scientific foundation behind what we believe is a transformative technology in therapeutic drug delivery.

CTT Pharma – 813-606-0060